Cargando…
Clinical Considerations for the Management of Androgen Indifferent Prostate Cancer
BACKGROUND: Many systemic therapies for advanced prostate cancer work by disrupting androgen receptor signaling. Androgen indifferent prostate cancer (AIPC) variants, including aggressive variant prostate cancer (AVPC), neuroendocrine prostate cancer (NEPC), and double negative prostate cancer (DNPC...
Autores principales: | Berchuck, Jacob E., Viscuse, Paul V., Beltran, Himisha, Aparicio, Ana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353003/ https://www.ncbi.nlm.nih.gov/pubmed/33568748 http://dx.doi.org/10.1038/s41391-021-00332-5 |
Ejemplares similares
-
Drivers of AR indifferent anti-androgen resistance in prostate cancer cells
por: Handle, Florian, et al.
Publicado: (2019) -
ONECUT2 as a new therapeutic target in androgen receptor-indifferent prostate cancer
por: Freeman, Michael R., et al.
Publicado: (2019) -
Multiple metastases of androgen indifferent prostate cancer in the urinary tract: two case reports and a literature review
por: Masuda, Tsukasa, et al.
Publicado: (2022) -
The Doctor's Indifference
Publicado: (1916) -
Indifference of Patients
Publicado: (1897)